Helsinn Group Announces Upcoming Presentation of Phase 3b Data of NEPA (fosnetupitant / palonosetron) IV at ASCO 2019
Lugano, Switzerland, May 31 (Korea Bizwire) – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the data on the intravenous (IV) formulation of NEPA (Akynzeo®) will be presented as poster at the American Society of Clinical Oncology (ASCO) Congress in June 2019 on the poster session Symptoms and Survivorship. [...]